Human biospecimens, as any cancer researcher will tell you, are a foundational resource in basic and clinical cancer research. And with the launch last year of President Obama's Precision Medicine Initiative and his announcement in January about the launch of the National Cancer Moonshot Initiative, NCI-supported biospecimen programs have taken on renewed importance.
Quality biospecimens are critical to achieving the type of progress envisioned by both of these initiatives, whether it's for conducting genomic analyses that will allow us to better understand cancer progression, discovering and validating biomarkers that can predict prognosis or response to therapy, or identifying new targets for therapy.
from Cancer via ola Kala on Inoreader http://ift.tt/1UOKnsc
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου